MARKET

BTX

BTX

Brooklyn ImmunoTherapeutics Inc
AMEX

Real-time Quotes | Nasdaq Last Sale

8.90
-0.89
-9.09%
After Hours: 9.14 +0.24 +2.70% 19:55 04/21 EDT
OPEN
9.68
PREV CLOSE
9.79
HIGH
9.84
LOW
8.62
VOLUME
1.44M
TURNOVER
--
52 WEEK HIGH
15.52
52 WEEK LOW
1.880
MARKET CAP
369.48M
P/E (TTM)
-2.9327
1D
5D
1M
3M
1Y
5Y
SKLZ, LAZR, NFLX and DGLY among midday movers
Gainers: Welbilt (WBT) +40%.Timber Pharmaceuticals (TMBR) +35%.Skillz (SKLZ) +27%.Asensus Surgical (ASXC) +27%.inTEST (INTT) +24%.Mogo (MOGO) +20%.GreenBox POS (GBOX) +20%.MicroVision (MVIS) +20%.BioVie (BIVI) +19%.Luminar Technologies (LAZR) +19%.Losers: ...
Seekingalpha · 9h ago
Europe Stem Cells Market Industry Analysis, Size, Share, Growth, Trends, and Forecast 2021 - 2027 | Covid-19 Impact Analysis
Apr 21, 2021 (Heraldkeepers) -- Pre & Post Covid-19 Impact and Recovery Analysis (Estimates) is Covered in Stem Cells Market Research Report. "Global...
Heraldkeepers · 12h ago
Stem Cells Market is Expected to Reach US$ 17.79 Bn by the end of 2027
Apr 20, 2021 (Market Stats News via COMTEX) -- The global stem cells market size is likely to reach USD 17.79 billion by 2027 and is anticipated to grow with...
Market Stats News · 1d ago
Brooklyn ImmunoTherapeutics Reports Inducement Grants
Business Wire · 2d ago
Clover Health Investments, Harrow Health leads healthcare gainers; Editas Medicine, Timber Pharmaceuticals among major losers
Gainers: Clover Health Investments (CLOV) +20%, Harrow Health (HROW) +12%, Brooklyn ImmunoTherapeutics (BTX) +8%, Evoke Pharma (EVOK) +8%, F-star Therapeutics (FSTX) +7%.Losers: Editas Medicine (EDIT) -15%, Timber Pharmaceuticals (TMBR) -14%, Trevena (TRVN...
Seekingalpha · 5d ago
DJ Brooklyn ImmunoTherapeutics Up; Pays $1M Towards Acquisition of License for mRNA Technology
Dow Jones · 5d ago
Mid-Morning Market Update: Markets Mostly Higher; Morgan Stanley Beats Q1 Expectations
Following the market opening Friday, the Dow traded up 0.30% to 34,138.98 while the NASDAQ fell 0.30% to 13,996.20. The S&P also rose, gaining 0.10% to 4,174.56.
Benzinga · 5d ago
Brooklyn ImmunoTherapeutics Pays $1 Million Towards Acquisition of License for mRNA Technology Platform to Develop Genetically Edited Cells for Multiple Cancers and Blood Disorders
Brooklyn ImmunoTherapeutics Pays $1 Million Towards Acquisition of License for mRNA Technology Platform to Develop Genetically Edited Cells
Business Wire · 6d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BTX. Analyze the recent business situations of Brooklyn ImmunoTherapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BTX stock price target is 5.50 with a high estimate of 5.50 and a low estimate of 5.50.
EPS
Institutional Holdings
Institutions: 14
Institutional Holdings: 789.44K
% Owned: 1.90%
Shares Outstanding: 41.51M
TypeInstitutionsShares
Increased
2
13.98K
New
3
319.28K
Decreased
1
3.44K
Sold Out
1
4
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.80%
Pharmaceuticals & Medical Research
+1.49%
Key Executives
Chairman/Director
Luba Greenwood
President/Chief Executive Officer
Howard Federoff
Executive Vice President
Lynn Mason
Other
Ronald Guido
Director
Charles Cherington
Director
George Denny
Director
Yiannis Monovoukas
No Data
About BTX
Brooklyn ImmunoTherapeutics, Inc. (Brooklyn), formerly NTN Buzztime, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on cytokine-based therapies in treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. Brooklyn is engaged in developing IRX-2, a cytokine-based therapy, to treat patients with head and neck cancer. IRX-2 is an allogeneic, reproducible, primary, human cell-derived Interleukin-2 (IL-2) therapeutic with multiple active cytokine components that act on various parts of the immune system, to activate the entire tumor microenvironment. In addition to IL-2, IRX-2 contains multiple human cytokines that promote or enhance an immune response. IRX-2 is administered as an injection around lymph node beds.

Webull offers kinds of Brooklyn Immunotherapeutics Inc stock information, including AMEX:BTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BTX stock methods without spending real money on the virtual paper trading platform.